Alzamend Neuro
ALZN
15 hedge funds and large institutions have $1.99M invested in Alzamend Neuro in 2021 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 3 closing their positions.
233% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 3
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
88% more funds holding
Funds holding: 8 → 15 (+7)
0% more ownership
Funds ownership: 0% → 0% (+0%)
23% less capital invested
Capital invested by funds: $2.58M → $1.99M (-$596K)
72% less call options, than puts
Call options by funds: $215K | Put options by funds: $767K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
+$703K |
| 2 |
SCA
Sassicaia Capital Advisers
Jericho,
New York
|
+$379K |
| 3 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$209K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$187K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$143K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
-$389K |
| 2 |
Jane Street
New York
|
-$324K |
| 3 |
TSS
Two Sigma Securities
New York
|
-$140K |
| 4 |
VF
Virtu Financial
New York
|
-$135K |
| 5 |
Wells Fargo
San Francisco,
California
|
-$2K |
ALZN Hedge Fund Activity: Q3 2021 in Review
15 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Alzamend Neuro (ALZN) for Q3 2021, worth a combined $1.99M — down 23% from $2.58M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new ALZN positions and 3 closed out — a net gain of 7 holders — while 3 added to existing stakes and 1 trimmed.
The largest buyer was Two Sigma Investments, opening a new position worth an estimated $703K. The largest seller was Geode Capital Management, exiting entirely with an estimated $389K sold.
- 15 institutional investors held Alzamend Neuro (ALZN) as of Q3 2021, up from 8 in Q2 2021.
- Funds reported $1.99M of Alzamend Neuro stock for Q3 2021, down 23% quarter-over-quarter.
- 10 funds opened new Alzamend Neuro positions in Q3 2021 and 3 closed out, a net change of +7 holders.
- The largest Alzamend Neuro buyer in Q3 2021 was Two Sigma Investments, an estimated $703K added.
- The largest Alzamend Neuro seller in Q3 2021 was Geode Capital Management, an estimated $389K sold.
Based on aggregated 13F filings for Q3 2021.